Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.

Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5.

PMID:
24252045
[PubMed - in process]
2.

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.

Smolen JS, Avila JC, Aletaha D.

Ann Rheum Dis. 2012 May;71(5):687-93. doi: 10.1136/annrheumdis-2011-200395. Epub 2011 Nov 25.

PMID:
22121130
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:
22975733
[PubMed - indexed for MEDLINE]
5.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:
23637318
[PubMed - indexed for MEDLINE]
6.

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).

Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW.

Ann Rheum Dis. 2013 Jan;72(1):43-50. doi: 10.1136/annrheumdis-2011-201282. Epub 2012 May 5.

PMID:
22562983
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.

Ogata A, Hirano T, Hishitani Y, Tanaka T.

Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:27-42. doi: 10.4137/CMAMD.S7371. Epub 2012 Mar 5.

PMID:
22438671
[PubMed]
Free PMC Article
9.

Which Factors Influence Radiographic Progression During Treatment with Tumor Necrosis Factor Inhibitors in Clinical Practice? Results from 930 Patients with Rheumatoid Arthritis in the Nationwide Danish DANBIO Registry.

Ornbjerg LM, Ostergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.

J Rheumatol. 2014 Dec;41(12):2352-60. doi: 10.3899/jrheum.131299. Epub 2014 Oct 1.

PMID:
25274894
[PubMed - in process]
10.

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61. doi: 10.1002/acr.22384.

PMID:
24942540
[PubMed - in process]
Free Article
11.

Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis.

Alten R.

Ther Adv Musculoskelet Dis. 2011 Jun;3(3):133-49. doi: 10.1177/1759720X11407540.

PMID:
22870473
[PubMed]
Free PMC Article
12.

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review.

Al-Shakarchi I, Gullick NJ, Scott DL.

Patient Prefer Adherence. 2013 Jul 4;7:653-66. doi: 10.2147/PPA.S41433. Print 2013.

PMID:
23869169
[PubMed]
Free PMC Article
13.

Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data.

Hama M, Uehara T, Takase K, Ihata A, Ueda A, Takeno M, Shizukuishi K, Tateishi U, Ishigatsubo Y.

Rheumatol Int. 2012 May;32(5):1327-33. doi: 10.1007/s00296-011-1802-5. Epub 2011 Feb 4.

PMID:
21293859
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

Navarro-Millán I, Singh JA, Curtis JR.

Clin Ther. 2012 Apr;34(4):788-802.e3. doi: 10.1016/j.clinthera.2012.02.014. Epub 2012 Mar 22. Review.

PMID:
22444783
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.

Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K.

Mod Rheumatol. 2010 Feb;20(1):40-5. doi: 10.1007/s10165-009-0235-4. Epub 2009 Oct 3.

PMID:
19802651
[PubMed - indexed for MEDLINE]
16.

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.

Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y.

Mod Rheumatol. 2010 Aug;20(4):343-52. doi: 10.1007/s10165-010-0290-x. Epub 2010 May 18.

PMID:
20480201
[PubMed - indexed for MEDLINE]
17.

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.

Rheumatology (Oxford). 2014 Sep 16. pii: keu363. [Epub ahead of print]

PMID:
25231180
[PubMed - as supplied by publisher]
18.

Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis.

Nair SC, Bijlsma JW, van der Werf JH, van der Veen MJ, Linn-Rasker SP, Vreugdenhil S, Lafeber FP, Welsing PM.

J Rheumatol. 2013 Sep;40(9):1505-12. doi: 10.3899/jrheum.121346. Epub 2013 Jul 1.

PMID:
23818710
[PubMed - indexed for MEDLINE]
19.
20.

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T.

Ann Rheum Dis. 2007 Sep;66(9):1162-7. Epub 2007 May 7.

PMID:
17485422
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk